GLTO - Galecto Inc Debt to Book Capitalization Ratio

Galecto, Inc. (GLTO) is investing in costly R&D for drugs targeting metabolic disorders, as evidenced by the debt-to-book capitalization ratio, which currently stands at 0.22. Environmental compliance is maintained through the filtration of laboratory emissions. Business stability is supported by a strong staff of fibrosis experts whose competencies enable the efficient execution of clinical trials.

GLTO (Galecto Corporation) Debt to Book Value history from 07/04/2022 to 03/10/2026

Galecto Inc (GLTO) - metric breakdowns and financial figures

- price and consensus price forecast:

Stock Price Galecto, Inc.|GLTO - Analyst Consensus Forecast

- market capitalization data:

Market Value Galecto Corporation|GLTO - Value Adjusted for Debt and Cash

- book capitalization data:

Net Assets per Single Share Galecto|GLTO - Company Net Assets|Market Capitalization to Book Value Ratio galecto.com|GLTO - Company Total Assets

- debt and liquidity data:

Total Debt to Equity Ratio Galecto, Inc.|GLTO - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Galecto Corp|GLTO - Company Total Debt|Debts to Book Capitalization Galecto Corporation

Fundamental company analysis:Galecto, Inc. - GLTO

This indicator assesses the degree of financial stability by comparing total liabilities to equity. The metric determines the business's dependence on borrowed funds and the risk of insolvency. The historical trend of the debt-to-book capitalization ratio visualizes the balance between credit leverage and security. For Galecto, Inc. (GLTO), this is critical when transitioning to new clinical phases. Stabilization following program restructuring reduces the debt load, protecting the value of oncology patents.

Competitors of Galecto, Inc. (GLTO)